Report of Foreign Issuer (6-k)
July 05 2017 - 04:15PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of
Foreign Private Issuer
Pursuant to
Rule 13a-16
or
15d-16
of the Securities Exchange Act of 1934
July 5, 2017
PROQR
THERAPEUTICS N.V.
Zernikedreef 9
2333 CK
Leiden
The Netherlands
Tel: +31 88 166 7000
(Address, Including ZIP Code, and Telephone Number, Including Area Code, of Registrants Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of
Form 20-F
or
Form 40-F.
Form 20-F ☒
Form 40-F ☐
Indicate by check mark if the registrant is submitting the
Form 6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the
Form 6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐
On July 5, 2017, ProQR Therapeutics N.V. issued a press release titled, ProQR Drug
Candidate
QRX-411
for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. The
Company hereby incorporates by reference the information contained herein into the Companys registration statement on Form
F-3
(File
No. 333-207245).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
PROQR THERAPEUTICS N.V.
|
|
|
|
|
Date: July 5, 2017
|
|
|
|
By:
|
|
/s/ Smital Shah
|
|
|
|
|
|
|
Smital Shah
|
|
|
|
|
|
|
Chief Financial Officer
|
INDEX TO EXHIBITS
|
|
|
Number
|
|
Description
|
|
|
99.1
|
|
ProQRs Drug Candidate
QRX-411
for Usher Syndrome Receives Orphan Drug Designation from FDA and EMA.
|
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Feb 2024 to Mar 2024
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Mar 2023 to Mar 2024